Eagle Pharmaceutical (EGRX) 40.50 $EGRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eagle Pharmaceuticals Inc. - EGRX
PR Newswire - Wed Mar 30, 10:36AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(NASDAQ: EGRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
EGRX: 40.50 (+1.44)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eagle Pharmaceuticals Inc. (EGRX)
PR Newswire - Wed Mar 30, 10:13AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Eagle Pharmaceuticals Inc. ("Eagle" or "the Company" (NASDAQ: EGRX). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals and the National Institutes of Health (NIH/NIDA) Enter into Agreement to Explore Use of Ryanodex in MDMA (Ecstasy) and Methamphetamine Intoxication
BusinessWire - Mon Mar 28, 6:00AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company" today announced that it has entered into an agreement with the National Institutes of Health ("NIH" /National Institute on Drug Abuse ("NIDA" to explore the use of Ryanodex(R) in the treatment of hyperthermia related to MDMA ("Ecstasy" and Methamphetamine intoxication, which is a life-threatening condition mostly affecting adolescents and young adults. The preclinical studies will be conducted by NIDA beginning in the summer of 2016 utilizing a well-characterized animal model. Initial results of the focused studies are anticipated in late 2016 or early 2017.
EGRX: 40.50 (+1.44)
FDA Does Not Grant Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
BusinessWire - Mon Mar 28, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company" announced today that the U.S. Food and Drug Administration (FDA) has denied Eagle's request for seven years of orphan drug exclusivity in the U.S., for BENDEKA(TM) (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. BENDEKA was approved in December 2015 for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Down on CRL for Kangio from FDA
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:12PM CDT
Eagle Pharmaceuticals (EGRX) announced that it has received a CRL for its blood clot preventing drug, Kangio, from the FDA.
MDCO: 31.77 (+0.78), HZNP: 16.57 (+0.56), EGRX: 40.50 (+1.44), ANIK: 44.72 (-0.26)
Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today
at The Street - Fri Mar 18, 3:24PM CDT
Eagle Pharmaceuticals (EGRX) stock closed down on heavy trading volume Friday after the FDA rejected its new drug application for its blood thinner drug Kangio.
EGRX: 40.50 (+1.44)
Here's Why Eagle Pharmaceuticals' Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 18, 2:54PM CDT
Source: Flickr via user zhouxuan12345678. What : As of 12:10 p.m. EST, Eagle Pharmaceuticals ' stock was down by more than 20% on higher-than-normal volume. The catalyst driving the drugmaker's shares lower today was the news that the U.S. Food...
MDC: 25.06 (+0.35), EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug
at The Street - Fri Mar 18, 11:17AM CDT
Eagle Pharmaceuticals (EGRX) stock is sinking on Friday afternoon as the FDA rejected the company’s drug Kangio, which prevents blood clots in some patients undergoing heart surgery.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application
BusinessWire - Fri Mar 18, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) ("Eagle" or the "Company" today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO(TM) (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use ("RTU" , stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial intended for use as an anticoagulant in patients: (1) undergoing percutaneous coronary intervention ("PCI" with use of glycoprotein IIb/IIIa inhibitor, (2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia ("HIT" and thrombosis syndrome ("HITTS" , and/or (3) with unstable angina undergoing percutaneous transluminal coronary angioplasty ("PTCA" .
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference
BusinessWire - Wed Feb 10, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company" (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference as follows:
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016
BusinessWire - Fri Feb 05, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq: EGRX) ("Eagle" announced today that the Company will release its 2015 fourth quarter and full year financial results on Thursday, February 25, 2016, before the market opens.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals elects Michael Moran as US head of Sales
M2 - Fri Feb 05, 5:02AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) revealed on Thursday the appointment of Michael Moran as US head of Sales with immediate effect.
EGRX: 40.50 (+1.44), GSK: 40.55 (-0.15)
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales
BusinessWire - Thu Feb 04, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (NASDAQ:EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S. Head of Sales, effective immediately.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals reports commercial launch of Non-Alcohol Docetaxel Injection in the US
M2 - Wed Feb 03, 3:45AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Tuesday the shipment and commercial availability of Alcohol-Free Docetaxel Injection for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula
BusinessWire - Tue Feb 02, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company" (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection ("Docetaxel Injection" . Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
EGRX: 40.50 (+1.44)
FDA Grants Fast Track Designation to RYANODEX for Treatment of Exertional Heat Stroke; Fast Track Designation Highlights Serious, Unmet Medical Need that Exists for Patients with EHS
BusinessWire - Mon Feb 01, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company" (NASDAQ:EGRX) today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its RYANODEX(R) (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS" , an investigational new indication for the product.
EGRX: 40.50 (+1.44)
Teva & Eagle Pharmaceuticals partnership unveils Injection for CLL & NHL patients
M2 - Fri Jan 29, 4:09AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA) and Eagle Pharmaceuticals (Nasdaq:EGRX) jointly reported on Thursday the commercial launch of BENDEKA for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44)
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA(TM) (bendamustine hydrochloride) Injection
BusinessWire - Thu Jan 28, 10:16AM CST
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today the commercial availability of BENDEKA(TM), (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 12.81 (+0.69), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), BMY: 63.88 (+0.44), EGRX: 40.50 (+1.44), GSK: 40.55 (-0.15), SNTA: 0.24 (-0.01), MRK: 52.91 (-0.31), AVEO: 0.92 (-0.02), TCON: 6.99 (+0.11), NVS: 72.44 (-0.11), FPRX: 40.63 (+0.79)
Best Small-Cap Stocks of 2015
Beth McKenna, The Motley Fool - Motley Fool - Tue Jan 12, 7:00AM CST
While the overall stock market was flat in 2015, there were some huge winners, especially among smaller company stocks. That's because it's easier for such companies to grow revenue and earnings faster on a percentage basis than it is for larger...
NHTC: 33.15 (-1.69), NPTN: 14.04 (+0.24), TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44), EXEL: 4.00 (+0.10)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eagle Pharmaceuticals Inc. - EGRX
PR Newswire - Wed Mar 30, 10:36AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(NASDAQ: EGRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. EGRX: 40.50 (+1.44)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eagle Pharmaceuticals Inc. (EGRX)
PR Newswire - Wed Mar 30, 10:13AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Eagle Pharmaceuticals Inc. ("Eagle" or "the Company"
(NASDAQ: EGRX). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals and the National Institutes of Health (NIH/NIDA) Enter into Agreement to Explore Use of Ryanodex in MDMA (Ecstasy) and Methamphetamine Intoxication
BusinessWire - Mon Mar 28, 6:00AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company"
today announced that it has entered into an agreement with the National Institutes of Health ("NIH" /National Institute on Drug Abuse ("NIDA" to explore the use of Ryanodex(R) in the treatment of hyperthermia related to MDMA ("Ecstasy" and Methamphetamine intoxication, which is a life-threatening condition mostly affecting adolescents and young adults. The preclinical studies will be conducted by NIDA beginning in the summer of 2016 utilizing a well-characterized animal model. Initial results of the focused studies are anticipated in late 2016 or early 2017. EGRX: 40.50 (+1.44)
FDA Does Not Grant Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
BusinessWire - Mon Mar 28, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company"
announced today that the U.S. Food and Drug Administration (FDA) has denied Eagle's request for seven years of orphan drug exclusivity in the U.S., for BENDEKA(TM) (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. BENDEKA was approved in December 2015 for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established. EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Down on CRL for Kangio from FDA
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:12PM CDT
Eagle Pharmaceuticals (EGRX) announced that it has received a CRL for its blood clot preventing drug, Kangio, from the FDA.
MDCO: 31.77 (+0.78), HZNP: 16.57 (+0.56), EGRX: 40.50 (+1.44), ANIK: 44.72 (-0.26)
Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today
at The Street - Fri Mar 18, 3:24PM CDT
Eagle Pharmaceuticals (EGRX) stock closed down on heavy trading volume Friday after the FDA rejected its new drug application for its blood thinner drug Kangio.
EGRX: 40.50 (+1.44)
Here's Why Eagle Pharmaceuticals' Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 18, 2:54PM CDT
Source: Flickr via user zhouxuan12345678. What : As of 12:10 p.m. EST, Eagle Pharmaceuticals ' stock was down by more than 20% on higher-than-normal volume. The catalyst driving the drugmaker's shares lower today was the news that the U.S. Food...
MDC: 25.06 (+0.35), EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug
at The Street - Fri Mar 18, 11:17AM CDT
Eagle Pharmaceuticals (EGRX) stock is sinking on Friday afternoon as the FDA rejected the company’s drug Kangio, which prevents blood clots in some patients undergoing heart surgery.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application
BusinessWire - Fri Mar 18, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) ("Eagle" or the "Company"
today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO(TM) (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use ("RTU" , stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial intended for use as an anticoagulant in patients: (1) undergoing percutaneous coronary intervention ("PCI" with use of glycoprotein IIb/IIIa inhibitor, (2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia ("HIT" and thrombosis syndrome ("HITTS" , and/or (3) with unstable angina undergoing percutaneous transluminal coronary angioplasty ("PTCA" . EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference
BusinessWire - Wed Feb 10, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company"
(NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference as follows: EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016
BusinessWire - Fri Feb 05, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(Nasdaq: EGRX) ("Eagle" announced today that the Company will release its 2015 fourth quarter and full year financial results on Thursday, February 25, 2016, before the market opens. EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals elects Michael Moran as US head of Sales
M2 - Fri Feb 05, 5:02AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) revealed on Thursday the appointment of Michael Moran as US head of Sales with immediate effect.
EGRX: 40.50 (+1.44), GSK: 40.55 (-0.15)
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales
BusinessWire - Thu Feb 04, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(NASDAQ:EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S. Head of Sales, effective immediately. EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals reports commercial launch of Non-Alcohol Docetaxel Injection in the US
M2 - Wed Feb 03, 3:45AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Tuesday the shipment and commercial availability of Alcohol-Free Docetaxel Injection for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.
EGRX: 40.50 (+1.44)
Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula
BusinessWire - Tue Feb 02, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company"
(NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection ("Docetaxel Injection" . Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. EGRX: 40.50 (+1.44)
FDA Grants Fast Track Designation to RYANODEX for Treatment of Exertional Heat Stroke; Fast Track Designation Highlights Serious, Unmet Medical Need that Exists for Patients with EHS
BusinessWire - Mon Feb 01, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company"
(NASDAQ:EGRX) today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its RYANODEX(R) (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS" , an investigational new indication for the product. EGRX: 40.50 (+1.44)
Teva & Eagle Pharmaceuticals partnership unveils Injection for CLL & NHL patients
M2 - Fri Jan 29, 4:09AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA) and Eagle Pharmaceuticals (Nasdaq:EGRX) jointly reported on Thursday the commercial launch of BENDEKA for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44)
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA(TM) (bendamustine hydrochloride) Injection
BusinessWire - Thu Jan 28, 10:16AM CST
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today the commercial availability of BENDEKA(TM), (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 12.81 (+0.69), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), BMY: 63.88 (+0.44), EGRX: 40.50 (+1.44), GSK: 40.55 (-0.15), SNTA: 0.24 (-0.01), MRK: 52.91 (-0.31), AVEO: 0.92 (-0.02), TCON: 6.99 (+0.11), NVS: 72.44 (-0.11), FPRX: 40.63 (+0.79)
Best Small-Cap Stocks of 2015
Beth McKenna, The Motley Fool - Motley Fool - Tue Jan 12, 7:00AM CST
While the overall stock market was flat in 2015, there were some huge winners, especially among smaller company stocks. That's because it's easier for such companies to grow revenue and earnings faster on a percentage basis than it is for larger...
NHTC: 33.15 (-1.69), NPTN: 14.04 (+0.24), TEVA: 53.51 (-0.89), EGRX: 40.50 (+1.44), EXEL: 4.00 (+0.10)
